Cellyan Biotechnology (HKPD) Payables (2024 - 2026)
Cellyan Biotechnology (HKPD) posted quarterly Payables of $1.6 million for Q3 2025, down 12.09% year-over-year from $1.8 million in Q3 2024, and down 27.81% quarter-over-quarter from $2.2 million in Q1 2025.
Cellyan Biotechnology (HKPD) Payables (2024 - 2026) Analysis & Trends
Cellyan Biotechnology (HKPD) has reported Payables for 2 consecutive years, with $1.6 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Payables fell 12.09% year-over-year to $1.6 million; the TTM figure through Sep 2025 stood at $1.6 million (down 12.09% YoY), while the FY2025 annual figure was $2.2 million, up 51.17% from the prior year.
- Payables eased to $1.6 million in Q3 2025 per HKPD's latest filing, from $2.2 million in the prior quarter.
- Across five years, Payables topped out at $2.2 million in Q1 2025 and bottomed at $1.5 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Mckesson | 100.02 Bn | 94.85 Bn | 3.69 Bn | 63.73 Bn |
| 2 | Cencora | 60.88 Bn | 58.06 Bn | 3.61 Bn | 54.70 Bn |
| 3 | Cardinal Health | 54.14 Bn | 49.29 Bn | 2.56 Bn | 38.28 Bn |
| 4 | Henry Schein | 10.05 Bn | 9.90 Bn | 1.10 Bn | 2.16 Bn |
| 5 | Akso Health | 737.16 Mn | 736.96 Mn | - | - |
| 6 | Edap Tms | 159.12 Mn | 137.58 Mn | 7.34 Mn | 1.86 Mn |
| 7 | Accendra Health | 100.85 Mn | 93.20 Mn | 263.41 Mn | 352.80 Mn |
| 8 | 111 | 32.10 Mn | -26.65 Mn | 18.18 Mn | 175.05 Mn |
| 9 | Cosmos Health | 12.73 Mn | 10.29 Mn | 1.51 Mn | 15.72 Mn |
| 10 | Cellyan Biotechnology | 6.55 Mn | 6.32 Mn | - | 873,941.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 873,941.00 |
| Sep 30, 2025 | 1.58 Mn |
| Mar 31, 2025 | 2.19 Mn |
| Sep 30, 2024 | 1.80 Mn |
| Mar 31, 2024 | 1.45 Mn |